Progress in pharmacotherapy of thrombosis

Polish Journal of Pharmacology

Volumn 55, Issue 4, 2003, Pages 523-533

  Labuzek, Krzysztof ^a   Krysiak, Robert ^a   Okopien, Bogusław ^a   Herman, Zbigniew S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adhesion; Aggregation; Coagulation system; Hemostasis; Thrombosis

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; ABCIXIMAB; ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; DAZOXIBEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; NITRIC OXIDE; PROSTANOID; PYRIDINE DERIVATIVE; RIDOGREL; ROXIFIBAN; THROMBIN INHIBITOR; THROMBOPLASTIN; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VON WILLEBRAND FACTOR; XEMILOFIBAN; YM 337;

BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG EMBOLISM; MORBIDITY; MORTALITY; NEUTROPENIA; RASH; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTOPENIC PURPURA; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0141502034     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Abraham E., Reinhart K., Svoboda P., Seibert A., Olthoff D., Dal Nogare A., Postier R., Hempelmann G., Butler T., Martin E., Zwingelstein C., Percell S., Shu V., Leighton A., Creasey A.A.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med., 2001, 29, 2081-2089.
2. Andrews R.K.: The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb. Haemost., 1999, 82, 357-364.
3. Bauer K.A., Eriksson B.I., Lassen M.R., Turpie A.G.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med., 2001, 345, 1305-1310.
4. Becker B.H., Miller J.L.: Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig. Blood, 1989, 74, 690-694.
5. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., Fisher C.J. Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 2001, 344, 699-709.
6. Brener S.J., Barr L.A., Burchenal J.E., Katz S., George B.S., Jones A.A., Cohen E.D., Gainey P.C., White H.J., Cheek H.B., Moses J.W., Moliterno D.J., Effron M.B., Topol E.J.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation, 1998, 98, 734-741.
7. Buring J.E., Hennekens C.H.: Prevention of cardiovascular disease: risks and benefits of aspirin. J. Gen. Intern. Med., 1990, 5, 54-57.
8. Cauwenberghs N., Meiring M., Vauterin S., van Wyk V., Lamprecht S., Roodt J.P., Novak L., Harsfalvi J., Deckmyn H., Kotze H.F.: Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in non human primates. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1347-1353.
9. Chan A.W., Moliterno D.J.: Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. Curr. Opin. Cardiol., 2001, 16, 375-383.
10. Clemetson K.J.: Platelet collagen receptors: a new target for inhibition? Haemostasis, 1999, 29, 16-26.
11. de Jonge E., Dekkers P.E., Creasey A.A., Hack C.E., Paulson S.K., Karim A., Kesecioglu J., Levi M., van Deventer S.J., van Der Poll T.: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood, 2000, 95, 1124-1129.
12. Depraetere H., Kerekes A., Deckmyn H.: The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1(GPIa/IIa)-I-domain binding to collagen in a different manner. Thromb. Haemost., 1999, 82, 1160-1163.
13. Di Carlo V., Agnelli G., Prandoni P., Coccheri S., Gensini G.F., Gianese F., Mannucci P.M.: Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group. Thromb. Haemost., 1999, 82, 30-34.
14. Eriksson B.I., Bauer K.A., Lassen MR., Turpie A.G.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med., 2001, 345, 1298-1304.
15. Eriksson B.I., Bergqvist D., Kalebo P., Dahl O.E., Lindbratt S., Bylock A., Frison L., Eriksson U.G., Welin L., Gustafsson D.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet, 2002, 360, 1441-1447.
16. Fahey T., Peters T.J.: Interpretation of thrombosis prevention trial. Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet, 1998, 351, 233-241.
17. Fox I., Dawson A., Loynds P., Eisner J., Findlen K., Levin E., Hanson D., Mant T., Wagner J., Maraganore J.: Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb. Haemost., 1993, 69, 157-163.
18. Gachet A.: ADP receptors and their inhibition. Thromb. Haemost., 2001, 86, 222-232.
19. Gresele P., Agnelli G.: Novel approaches to the treatment of thrombosis. Trends Pharmacol. Sci., 2002, 23, 25-32.
20. Gurevitz O., Goldfarb A., Hod H., Feldman M., Shenkman B., Varon D., Eldar M., Inbal A.: Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 200-207.
21. Hachinski V.: Aspirin and the primary prevention of myocardial infarction and stroke. Arch. Neurol., 1990, 47, 1354.
22. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351, 1755-1762.
23. Harker L.A., Hanson S.R., Wilcox J.N., Kelly A.B.: Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis, 1996, 26, Suppl 1, 76-82.
24. Hilpert K., Ackermann J., Banner D.W., Gast A., Gubernator K., Hadvary P., Labler L., Muller K., Schmid G., Tschopp T.B.: Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem., 1994, 37, 3889-3901.
25. Hull R.D., Pineo G.F.: Hirudin versus heparin and low-molecular-weight heparin. J. Lab. Clin. Med., 1998, 132, 171-174.
26. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H.: Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med., 2002, 26, 969-974.
27. Kageyama S., Yamamoto H., Yoshimoto R.: Anti-human von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2303-2308.
28. Keller P.M., Schultz L.D., Condra C., Karczewski J., Connolly T.M.: An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. Cloning of the cDNA and expression. J. Biol. Chem., 1992, 267, 6899-6904.
29. Kleinschmidt K.: Acute coronary syndromes: pharmacotherapeutic interventions - guidelines for management of patients subjected to conservative and invasive treatment (Polish). Nowości Kardiologiczne, 2001, 1, 10.
30. Lassen M.R., Bauer K.A., Eriksson B.I., Turpie A.G.: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet, 2002, 359, 1715-1720.
31. Lee A., Agnelli G., Büller H., Ginsberg J., Heit J., Rote W., Vlasuk G., Costantini L., Julian J., Comp P., van der Meer J., Piovella F., Raskob G., Gent M.: Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation, 2001, 104, 74-78.
32. Matsuno H., Kozawa O., Niwa M., Tanabe K., Ichimaru K., Takiguchi Y., Yokota M., Hayashi H., Uematsu T.: Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb. Haemost., 1998, 79, 865-871.
33. McKeage K., Plosker G.L.: Argatroban. Drugs, 2001, 61, 515-522.
34. Momi S., Emerson M., Paul W., Leone M., Mezzasoma A.M., Del Soldato P., Page C.P., Gresele P.: Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide releasing aspirin. Eur. J. Pharmacol., 2000, 397, 177-186.
35. Monassier J.P., Hamon M., Elias J., Maillard L., Spaulding C., Raynaud P., Cribier A., Barragan P., Juliard J. M., Lefevre T., Aubry P., Faugier J. P., Masquet C., Rioux P., Bedossa M., Joly P., Petiteau P.Y., Royer T., Morice M.C., Roriz R., Cattan S., Meyer P., Blanchard D., Khalife K.: Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study. French Registry of Stenting in Acute Myocardial Infarction. Catheter. Cardiovasc. Diagn., 1997, 42, 243-248.
36. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., Boulenc J.M., Morice M.C., Maillard L., Pansieri M., Choussat R., Pinton P.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. ADMIRAL Investigators - Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. N. Engl. J. Med., 2001, 344, 1895-1903.
37. Mousa S.A.: Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discov. Today, 1999, 4, 552-561.
38. Nieswandt B., Schulte V., Bergmeier W., Mokhtari-Nejad R., Rackebrandt K., Cazenave J.P., Ohlmann P., Gachet C., Zirngibl H.: Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J. Exp. Med., 2001, 193, 459-469.
39. Orford J.L., Holmes D.R. Jr.: Abciximab readministration. Rev. Cardiovasc. Med., 2002, 3, 67-70.
40. Pineo G.F., Hull R.D., Marder V.J.: Orally active heparin and low-molecular-weight heparin. Curr. Opin. Pulmon. Med., 2001, 7, 344-348.
41. Pollina E.: Design and synthesis of RGD mimetics as potent inhibitors of platelet aggregation. J. Undergrad. Sci., 1996, 3, 119-126.
42. Rang H.P., Dale M.M., Ritter J.M.: Clinical Pharmacology (Polish). Czelej Publishing, Lublin, 2001.
43. Rivera T.M., Leone-Bay A., Paton D.R., Leipold H.R., Baughman R.A.: Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm. Res., 1997, 14, 1830-1834.
44. Schömig A.: Randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med., 1996, 334, 1084-1089.
45. Shapiro M.J., Weiss E.J., Farugi T.R., Coughlin S.R.: Protease-activated receptor 1 and 4 are shut off with distinct kinetics after activation by thrombin. J. Biol. Chem., 2000, 275, 25216-25221.
46. Storey F.: The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets, 2001, 12, 197-209.
47. The Ridogrel Versus Aspirin Patency Trial (RAPT). Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation, 1994, 89, 588-595.
48. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R.: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Arch. Int. Med., 2002, 162, 1833-1840.
49. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet, 2002, 359, 1721-1726.
50. Wallace J.L., Ignarro L.J., Fiorucci S.: Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug. Discov., 2002, 1, 375-382.
51. Watson S.P.: Collagen receptor signalling in platelets and megakaryocytes. Thromb. Haemost., 1999, 82, 365-376.
52. Weitz J.I., Buller H.R.: Direct thrombin inhibitors in acute coronary syndromes. Present and future. Circulation, 2002, 105, 1004-1011.
53. Yao S.K., Ober J.C., Garfinkel L.I., Hagay Y., Ezov N., Ferguson J.J., Anderson H.V., Panet A., Gorecki M., Buja L.M.: Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation, 1994, 89, 2822-2828.